DESKi has secured $6 million in funding to support the launch of its FDA-approved AI-powered cardiac imaging software, HeartFocus, aiming to democratize access to early cardiac care globally.

Information on the Target

DESKi is a health technology company specializing in the development of AI-powered diagnostic tools in collaboration with clinicians and researchers. The company recently announced the closure of a $6 million funding round aimed at facilitating the launch of its FDA-approved cardiac imaging software, HeartFocus, in the United States and globally.

The funding round was led by Racine², an impact-focused fund managed by Serena and Makesense. It also saw participation from notable investors such as BNP Paribas Développement, Épopée Gestion, Good Only Ventures, Better Angle, and NACO, the regional fund of Nouvelle-Aquitaine advised by M Capital. This group of leading European investors in the health and impact sector not only brings financial backing but also a strong alignment with DESKi's vision of democratizing access to early, AI-based cardiac care on a global scale.

Industry Overview in the Target’s Specific Country

Cardiovascular diseases remain the leading cause of death in the United States and worldwide. Despite advancements in medical technology, access to echocardiography is often restricted du